Is There a Cardiovascular Rationale for the Use of Combined Vasopressin V1a/V2 Receptor Antagonists?

American Journal of Medicine

Volumn 119, Issue 7 SUPPL. 1, 2006, Pages

  Goldsmith, Steven R ^a  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

Congestive heart failure; V1a V2 receptor antagonist; Vasopressin receptor antagonist

Indexed keywords

AQUAPORIN; ARGIPRESSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; GROWTH FACTOR; INOTROPIC AGENT; LOOP DIURETIC AGENT; TOLVAPTAN; VASODILATOR AGENT; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ARTICLE; BLOOD VESSEL TONE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DIURESIS; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ELECTROLYTE DISTURBANCE; EXPECTATION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART STIMULATION; HEART VENTRICLE HYPERTROPHY; HORMONAL REGULATION; HUMAN; HYPERTENSION; HYPERVOLEMIA; HYPONATREMIA; HYPOTENSION; KIDNEY COLLECTING TUBULE; KIDNEY DYSFUNCTION; MITOGENESIS; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SODIUM BLOOD LEVEL; VASOCONSTRICTION; WATER RETENTION;

BLOOD VOLUME; HEART FAILURE, CONGESTIVE; HUMANS; RECEPTORS, VASOPRESSIN;

EID: 33745712350     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2006.05.015     Document Type: Article

References (19)

1. Goldsmith S.R. Therapeutics in congestive heart failure. from hemodynamics to neurohormones. In: Singal P.K., Dixon I.M.C., Kirshenbaum L.A., and Dhalla N.S. (Eds). Cardiac Remodeling and Failure (2003), Kluwer Academic Publishers, Boston 17-34
2. Lowes B.D., Gilbert E.M., Abraham W.T., et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 346 (2002) 1357-1365
3. Goldsmith S.R., Francis G.S., Cowley Jr. A.W., Goldenberg I.F., and Cohn J.N. Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J Am Coll Cardiol 8 (1986) 779-783
4. Creager M.A., Faxon D.P., Cutler S.S., Kohlmann O., Ryan T.J., and Gavras H. Contribution of vasopressin to vasoconstriction in patients with congestive heart failure. comparison with the renin-angiotensin system and the sympathetic nervous system. J Am Coll Cardiol 7 (1986) 758-765
5. Goldsmith S.R. Vasopressin. a therapeutic target in congestive heart failure?. J Card Fail 5 (1999) 347-356
6. 1A receptor. Eur J Pharmacol 391 (2000) 39-48
7. Fukuzawa J., Haneda T., and Kikuchi K. Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor. Mol Cell Biochem 195 (1999) 93-98
8. 2 receptor antagonists. J Mol Endocrinol 29 (2002) 1-9
9. Goldsmith S.R. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure. Am J Cardiol 95 suppl (2005) 14B-23B
10. Gheorghiade M., Gattis W.A., O'Connor C.M., et al., Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure. a randomized controlled trial. JAMA 291 (2004) 1963-1971
11. Weber K.T. Furosemide in the long-term management of heart failure. the good, the bad, and the uncertain. J Am Coll Cardiol 44 (2004) 1308-1310
12. Cooper H.A., Dries D.L., Davis C.E., Shen Y.L., and Domanski M.J. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 100 (1999) 1311-1315
13. McCurley J.M., Hanlon S.U., Wei S.K., Wedam E.F., Michalski M., and Haigney M.C. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol 44 (2004) 1301-1307
14. 2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 292 (2000) 288-294
15. Klein L., O'Connor C.M., Leimberger J.D., et al., OPTIME-CHF Investigators. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure. results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 111 (2005) 2454-2460
16. Naitoh M., Suzuki H., Murakami M., et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol 267 pt 2 (1994) H2245-H2254
17. 2 receptor blockade and ACE inhibition. Cardiovasc Res 54 (2002) 51-57
18. 2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104 (2001) 2417-2423
19. 2 antagonist (conivaptan) increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure. J Card Fail 11 suppl (2005) S120 Abstract 111